DMAC vs ROP · $157.4M cap vs P/E 41, rev $1.88B
DiaMedica Therapeutics Inc (DMAC) versus Roper Technologies, Inc. (ROP) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Roper Technologies, Inc. (ROP) is a software - application company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported ROP revenue for 2024-12-31 was $1.88B. Net income was $462.3M. Revenue was up 6.4% from 2024-09-30 to 2024-12-31. ROP currently screens at market cap $61.61B and trailing P/E 41.3.
DMAC currently screens at market cap $157.4M. ROP currently screens at market cap $61.61B and trailing P/E 41.3.
Not investment advice. Open the DMAC and ROP stock pages for the full models.
Not investment advice.